APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tumor Treatment Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Tumor Treatment Drug Market Outlook and Growth Opportunities 2026

2 January 2026213 pages

Choose your research edition.

Industry ResearchTumor Treatment Drug Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumor Treatment Drug Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Tumor Treatment Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumor Treatment Drug Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumor Treatment Drug Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Tumor Treatment Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Tumor Treatment Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tumor Treatment Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tumor Treatment Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Tumor Treatment Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Tumor Treatment Drug market include Astellas, Biogen Idec, Bristol-Myers Squibb, Celgene, Gilead Sciences, Ipsen, Merck & Co., Otsuka and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Tumor Treatment Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tumor Treatment Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tumor Treatment Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Tumor Treatment Drug market.

Tumor Treatment Drug Segment by Company

Astellas

Biogen Idec

Bristol-Myers Squibb

Celgene

Gilead Sciences

Ipsen

Merck & Co.

Otsuka

AstraZeneca

AbbVie

Amgen

Bayer

Pfizer

Eli Lilly

Roche

Merck KGaA

Novartis

Johnson & Johnson

Sanofi

Teva

Eisai

Takeda

Tumor Treatment Drug Segment by Type

Immunotherapy (Biologic Therapy)

Chemotherapy

Hormonal Therapy

Targeted Therapy

Others

Tumor Treatment Drug Segment by Application

Respiratory/Lung Cancer

Prostate Cancer

Breast Cancer

Gastrointestinal Cancer

Blood Cancer

Others

Tumor Treatment Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Tumor Treatment Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Tumor Treatment Drug key companies, revenue, market share, and recent developments.

3. To split the Tumor Treatment Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Tumor Treatment Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Tumor Treatment Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Tumor Treatment Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Treatment Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumor Treatment Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Treatment Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tumor Treatment Drug industry.

Chapter 3: Detailed analysis of Tumor Treatment Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Tumor Treatment Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Tumor Treatment Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Tumor Treatment Drug Industry Trends Table 2. Tumor Treatment Drug Industry Drivers Table 3. Tumor Treatment Drug Industry Opportunities and Challenges Table 4. Tumor Treatment Drug Industry Restraints Table 5. Global Tumor Treatment Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Tumor Treatment Drug Revenue Share by Company (2021-2026) Table 7. Global Tumor Treatment Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Tumor Treatment Drug Key Company Manufacturing Base & Headquarters Table 9. Global Tumor Treatment Drug Company, Product Type & Application Table 10. Global Tumor Treatment Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Tumor Treatment Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Immunotherapy (Biologic Therapy) Table 15. Significant Companies of Chemotherapy Table 16. Significant Companies of Hormonal Therapy Table 17. Significant Companies of Targeted Therapy Table 18. Significant Companies of Others Table 19. Global Tumor Treatment Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Tumor Treatment Drug Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Tumor Treatment Drug Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Tumor Treatment Drug Sales Value Share by Type (2021-2026) Table 23. Global Tumor Treatment Drug Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Respiratory/Lung Cancer Table 25. Significant Companies of Prostate Cancer Table 26. Significant Companies of Breast Cancer Table 27. Significant Companies of Gastrointestinal Cancer Table 28. Significant Companies of Blood Cancer Table 29. Significant Companies of Others Table 30. Global Tumor Treatment Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Tumor Treatment Drug Sales Value by Application (2021-2026) & (US$ Million) Table 32. Global Tumor Treatment Drug Sales Value by Application (2027-2032) & (US$ Million) Table 33. Global Tumor Treatment Drug Sales Value Share by Application (2021-2026) Table 34. Global Tumor Treatment Drug Sales Value Share by Application (2027-2032) Table 35. Global Tumor Treatment Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Tumor Treatment Drug Sales Value by Region (2021-2026) & (US$ Million) Table 37. Global Tumor Treatment Drug Sales Value Share by Region (2021-2026) Table 38. Global Tumor Treatment Drug Sales Value by Region (2027-2032) & (US$ Million) Table 39. Global Tumor Treatment Drug Sales Value Share by Region (2027-2032) Table 40. Global Tumor Treatment Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Tumor Treatment Drug Sales Value by Country (2021-2026) & (US$ Million) Table 42. Global Tumor Treatment Drug Sales Value Market Share by Country (2021-2026) Table 43. Global Tumor Treatment Drug Sales Value by Country (2027-2032) & (US$ Million) Table 44. Global Tumor Treatment Drug Sales Value Market Share by Country (2027-2032) Table 45. Astellas Company Information Table 46. Astellas Business Overview Table 47. Astellas Tumor Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Astellas Tumor Treatment Drug Product Portfolio Table 49. Astellas Recent Development Table 50. Biogen Idec Company Information Table 51. Biogen Idec Business Overview Table 52. Biogen Idec Tumor Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Biogen Idec Tumor Treatment Drug Product Portfolio Table 54. Biogen Idec Recent Development Table 55. Bristol-Myers Squibb Company Information Table 56. Bristol-Myers Squibb Business Overview Table 57. Bristol-Myers Squibb Tumor Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Bristol-Myers Squibb Tumor Treatment Drug Product Portfolio Table 59. Bristol-Myers Squibb Recent Development Table 60. Celgene Company Information Table 61. Celgene Business Overview Table 62. Celgene Tumor Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Celgene Tumor Treatment Drug Product Portfolio Table 64. Celgene Recent Development Table 65. Gilead Sciences Company Information Table 66. Gilead Sciences Business Overview Table 67. Gilead Sciences Tumor Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Gilead Sciences Tumor Treatment Drug Product Portfolio Table 69. Gilead Sciences Recent Development Table 70. Ipsen Company Information Table 71. Ipsen Business Overview Table 72. Ipsen Tumor Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Ipsen Tumor Treatment Drug Product Portfolio Table 74. Ipsen Recent Development Table 75. Merck & Co. Company Information Table 76. Merck & Co. Business Overview Table 77. Merck & Co. Tumor Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Merck & Co. Tumor Treatment Drug Product Portfolio Table 79. Merck & Co. Recent Development Table 80. Otsuka Company Information Table 81. Otsuka Business Overview Table 82. Otsuka Tumor Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Otsuka Tumor Treatment Drug Product Portfolio Table 84. Otsuka Recent Development Table 85. AstraZeneca Company Information Table 86. AstraZeneca Business Overview Table 87. AstraZeneca Tumor Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. AstraZeneca Tumor Treatment Drug Product Portfolio Table 89. AstraZeneca Recent Development Table 90. AbbVie Company Information Table 91. AbbVie Business Overview Table 92. AbbVie Tumor Treatment Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. AbbVie Tumor Treatment Drug Product Portfolio Table 94. AbbVie Recent Development Table 95. Amgen Company Information Table 96. Amgen Business Overview Table 97. Amgen Tumor Treatment Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Amgen Tumor Treatment Drug Product Portfolio Table 99. Amgen Recent Development Table 100. Bayer Company Information Table 101. Bayer Business Overview Table 102. Bayer Tumor Treatment Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Bayer Tumor Treatment Drug Product Portfolio Table 104. Bayer Recent Development Table 105. Pfizer Company Information Table 106. Pfizer Business Overview Table 107. Pfizer Tumor Treatment Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Pfizer Tumor Treatment Drug Product Portfolio Table 109. Pfizer Recent Development Table 110. Eli Lilly Company Information Table 111. Eli Lilly Business Overview Table 112. Eli Lilly Tumor Treatment Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Eli Lilly Tumor Treatment Drug Product Portfolio Table 114. Eli Lilly Recent Development Table 115. Roche Company Information Table 116. Roche Business Overview Table 117. Roche Tumor Treatment Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Roche Tumor Treatment Drug Product Portfolio Table 119. Roche Recent Development Table 120. Merck KGaA Company Information Table 121. Merck KGaA Business Overview Table 122. Merck KGaA Tumor Treatment Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Merck KGaA Tumor Treatment Drug Product Portfolio Table 124. Merck KGaA Recent Development Table 125. Novartis Company Information Table 126. Novartis Business Overview Table 127. Novartis Tumor Treatment Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Novartis Tumor Treatment Drug Product Portfolio Table 129. Novartis Recent Development Table 130. Johnson & Johnson Company Information Table 131. Johnson & Johnson Business Overview Table 132. Johnson & Johnson Tumor Treatment Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Johnson & Johnson Tumor Treatment Drug Product Portfolio Table 134. Johnson & Johnson Recent Development Table 135. Sanofi Company Information Table 136. Sanofi Business Overview Table 137. Sanofi Tumor Treatment Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Sanofi Tumor Treatment Drug Product Portfolio Table 139. Sanofi Recent Development Table 140. Teva Company Information Table 141. Teva Business Overview Table 142. Teva Tumor Treatment Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Teva Tumor Treatment Drug Product Portfolio Table 144. Teva Recent Development Table 145. Eisai Company Information Table 146. Eisai Business Overview Table 147. Eisai Tumor Treatment Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Eisai Tumor Treatment Drug Product Portfolio Table 149. Eisai Recent Development Table 150. Takeda Company Information Table 151. Takeda Business Overview Table 152. Takeda Tumor Treatment Drug Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Takeda Tumor Treatment Drug Product Portfolio Table 154. Takeda Recent Development Table 155. Research Programs/Design for This Report Table 156. Authors List of This Report Table 157. Secondary Sources Table 158. Primary Sources List of Figures Figure 1. Tumor Treatment Drug Product Image Figure 2. Global Tumor Treatment Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tumor Treatment Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Tumor Treatment Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Immunotherapy (Biologic Therapy) Image Figure 8. Chemotherapy Image Figure 9. Hormonal Therapy Image Figure 10. Targeted Therapy Image Figure 11. Others Image Figure 12. Global Tumor Treatment Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Tumor Treatment Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Tumor Treatment Drug Sales Value Share by Type (2021-2032) Figure 15. Respiratory/Lung Cancer Image Figure 16. Prostate Cancer Image Figure 17. Breast Cancer Image Figure 18. Gastrointestinal Cancer Image Figure 19. Blood Cancer Image Figure 20. Others Image Figure 21. Global Tumor Treatment Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Tumor Treatment Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 23. Global Tumor Treatment Drug Sales Value Share by Application (2021-2032) Figure 24. Global Tumor Treatment Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 25. Global Tumor Treatment Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 26. North America Tumor Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 27. North America Tumor Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Europe Tumor Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 29. Europe Tumor Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Asia-Pacific Tumor Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 31. Asia-Pacific Tumor Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. South America Tumor Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 33. South America Tumor Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Middle East & Africa Tumor Treatment Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Middle East & Africa Tumor Treatment Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. USA Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. USA Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. USA Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Canada Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Canada Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Canada Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Mexico Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Mexico Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Mexico Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Germany Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Germany Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Germany Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. France Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. France Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. France Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. U.K. Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. U.K. Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. U.K. Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Italy Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Italy Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Italy Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Spain Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Spain Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Spain Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Russia Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Russia Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Russia Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Netherlands Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Netherlands Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Netherlands Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Nordic Countries Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Nordic Countries Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Nordic Countries Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. China Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. China Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. China Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Japan Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Japan Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Japan Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. South Korea Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. South Korea Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. South Korea Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. India Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. India Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. India Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Australia Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Australia Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Australia Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Southeast Asia Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Southeast Asia Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Southeast Asia Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Brazil Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Brazil Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Brazil Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Argentina Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Argentina Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Argentina Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Chile Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Chile Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Chile Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Colombia Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Colombia Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Colombia Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Peru Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Peru Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Peru Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Saudi Arabia Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Saudi Arabia Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Israel Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Israel Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Israel Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. UAE Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. UAE Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. UAE Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Turkey Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Turkey Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Turkey Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Iran Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Iran Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Iran Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Egypt Tumor Treatment Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Egypt Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Egypt Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Years Considered Figure 121. Research Process Figure 122. Key Executives Interviewed

Scope & coverage.

Types
  • Immunotherapy (Biologic Therapy)
  • Chemotherapy
  • Hormonal Therapy
  • Targeted Therapy
  • Others
Applications
  • Respiratory/Lung Cancer
  • Prostate Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Blood Cancer
  • Others
Companies covered
  • Astellas
  • Biogen Idec
  • Bristol-Myers Squibb
  • Celgene
  • Gilead Sciences
  • Ipsen
  • Merck & Co.
  • Otsuka
  • AstraZeneca
  • AbbVie
  • Amgen
  • Bayer
  • Pfizer
  • Eli Lilly
  • Roche
  • Merck KGaA
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Teva
  • Eisai
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Tumor Treatment Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Tumor Treatment Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Tumor Treatment Drug Market Dynamics
  1. 2.1 Tumor Treatment Drug Industry Trends
  2. 2.2 Tumor Treatment Drug Industry Drivers
  3. 2.3 Tumor Treatment Drug Industry Opportunities and Challenges
  4. 2.4 Tumor Treatment Drug Industry Restraints
3 Tumor Treatment Drug Market by Company
  1. 3.1 Global Tumor Treatment Drug Company Revenue Ranking in 2025
  2. 3.2 Global Tumor Treatment Drug Revenue by Company (2021-2026)
  3. 3.3 Global Tumor Treatment Drug Company Ranking (2024-2026)
  4. 3.4 Global Tumor Treatment Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Tumor Treatment Drug Company Product Type and Application
  6. 3.6 Global Tumor Treatment Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Tumor Treatment Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Tumor Treatment Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Tumor Treatment Drug Market by Type
  1. 4.1 Tumor Treatment Drug Type Introduction
  2. 4.1.1 Immunotherapy (Biologic Therapy)
  3. 4.1.2 Chemotherapy
  4. 4.1.3 Hormonal Therapy
  5. 4.1.4 Targeted Therapy
  6. 4.1.5 Others
  7. 4.2 Global Tumor Treatment Drug Sales Value by Type
  8. 4.2.1 Global Tumor Treatment Drug Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Tumor Treatment Drug Sales Value by Type (2021-2032)
  10. 4.2.3 Global Tumor Treatment Drug Sales Value Share by Type (2021-2032)
5 Tumor Treatment Drug Market by Application
  1. 5.1 Tumor Treatment Drug Application Introduction
  2. 5.1.1 Respiratory/Lung Cancer
  3. 5.1.2 Prostate Cancer
  4. 5.1.3 Breast Cancer
  5. 5.1.4 Gastrointestinal Cancer
  6. 5.1.5 Blood Cancer
  7. 5.1.6 Others
  8. 5.2 Global Tumor Treatment Drug Sales Value by Application
  9. 5.2.1 Global Tumor Treatment Drug Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Tumor Treatment Drug Sales Value by Application (2021-2032)
  11. 5.2.3 Global Tumor Treatment Drug Sales Value Share by Application (2021-2032)
6 Tumor Treatment Drug Regional Value Analysis
  1. 6.1 Global Tumor Treatment Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tumor Treatment Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Tumor Treatment Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Tumor Treatment Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Tumor Treatment Drug Sales Value (2021-2032)
  7. 6.3.2 North America Tumor Treatment Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Tumor Treatment Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Tumor Treatment Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Tumor Treatment Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Tumor Treatment Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Tumor Treatment Drug Sales Value (2021-2032)
  16. 6.6.2 South America Tumor Treatment Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Tumor Treatment Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Tumor Treatment Drug Sales Value Share by Country, 2025 VS 2032
7 Tumor Treatment Drug Country-level Value Analysis
  1. 7.1 Global Tumor Treatment Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Tumor Treatment Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Tumor Treatment Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Tumor Treatment Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Tumor Treatment Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Tumor Treatment Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Tumor Treatment Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Astellas
  2. 8.1.1 Astellas Company Information
  3. 8.1.2 Astellas Business Overview
  4. 8.1.3 Astellas Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Astellas Tumor Treatment Drug Product Portfolio
  6. 8.1.5 Astellas Recent Developments
  7. 8.2 Biogen Idec
  8. 8.2.1 Biogen Idec Company Information
  9. 8.2.2 Biogen Idec Business Overview
  10. 8.2.3 Biogen Idec Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Biogen Idec Tumor Treatment Drug Product Portfolio
  12. 8.2.5 Biogen Idec Recent Developments
  13. 8.3 Bristol-Myers Squibb
  14. 8.3.1 Bristol-Myers Squibb Company Information
  15. 8.3.2 Bristol-Myers Squibb Business Overview
  16. 8.3.3 Bristol-Myers Squibb Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bristol-Myers Squibb Tumor Treatment Drug Product Portfolio
  18. 8.3.5 Bristol-Myers Squibb Recent Developments
  19. 8.4 Celgene
  20. 8.4.1 Celgene Company Information
  21. 8.4.2 Celgene Business Overview
  22. 8.4.3 Celgene Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Celgene Tumor Treatment Drug Product Portfolio
  24. 8.4.5 Celgene Recent Developments
  25. 8.5 Gilead Sciences
  26. 8.5.1 Gilead Sciences Company Information
  27. 8.5.2 Gilead Sciences Business Overview
  28. 8.5.3 Gilead Sciences Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Gilead Sciences Tumor Treatment Drug Product Portfolio
  30. 8.5.5 Gilead Sciences Recent Developments
  31. 8.6 Ipsen
  32. 8.6.1 Ipsen Company Information
  33. 8.6.2 Ipsen Business Overview
  34. 8.6.3 Ipsen Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Ipsen Tumor Treatment Drug Product Portfolio
  36. 8.6.5 Ipsen Recent Developments
  37. 8.7 Merck & Co.
  38. 8.7.1 Merck & Co. Company Information
  39. 8.7.2 Merck & Co. Business Overview
  40. 8.7.3 Merck & Co. Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck & Co. Tumor Treatment Drug Product Portfolio
  42. 8.7.5 Merck & Co. Recent Developments
  43. 8.8 Otsuka
  44. 8.8.1 Otsuka Company Information
  45. 8.8.2 Otsuka Business Overview
  46. 8.8.3 Otsuka Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Otsuka Tumor Treatment Drug Product Portfolio
  48. 8.8.5 Otsuka Recent Developments
  49. 8.9 AstraZeneca
  50. 8.9.1 AstraZeneca Company Information
  51. 8.9.2 AstraZeneca Business Overview
  52. 8.9.3 AstraZeneca Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca Tumor Treatment Drug Product Portfolio
  54. 8.9.5 AstraZeneca Recent Developments
  55. 8.10 AbbVie
  56. 8.10.1 AbbVie Company Information
  57. 8.10.2 AbbVie Business Overview
  58. 8.10.3 AbbVie Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AbbVie Tumor Treatment Drug Product Portfolio
  60. 8.10.5 AbbVie Recent Developments
  61. 8.11 Amgen
  62. 8.11.1 Amgen Company Information
  63. 8.11.2 Amgen Business Overview
  64. 8.11.3 Amgen Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Amgen Tumor Treatment Drug Product Portfolio
  66. 8.11.5 Amgen Recent Developments
  67. 8.12 Bayer
  68. 8.12.1 Bayer Company Information
  69. 8.12.2 Bayer Business Overview
  70. 8.12.3 Bayer Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bayer Tumor Treatment Drug Product Portfolio
  72. 8.12.5 Bayer Recent Developments
  73. 8.13 Pfizer
  74. 8.13.1 Pfizer Company Information
  75. 8.13.2 Pfizer Business Overview
  76. 8.13.3 Pfizer Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Pfizer Tumor Treatment Drug Product Portfolio
  78. 8.13.5 Pfizer Recent Developments
  79. 8.14 Eli Lilly
  80. 8.14.1 Eli Lilly Company Information
  81. 8.14.2 Eli Lilly Business Overview
  82. 8.14.3 Eli Lilly Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Eli Lilly Tumor Treatment Drug Product Portfolio
  84. 8.14.5 Eli Lilly Recent Developments
  85. 8.15 Roche
  86. 8.15.1 Roche Company Information
  87. 8.15.2 Roche Business Overview
  88. 8.15.3 Roche Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Roche Tumor Treatment Drug Product Portfolio
  90. 8.15.5 Roche Recent Developments
  91. 8.16 Merck KGaA
  92. 8.16.1 Merck KGaA Company Information
  93. 8.16.2 Merck KGaA Business Overview
  94. 8.16.3 Merck KGaA Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Merck KGaA Tumor Treatment Drug Product Portfolio
  96. 8.16.5 Merck KGaA Recent Developments
  97. 8.17 Novartis
  98. 8.17.1 Novartis Company Information
  99. 8.17.2 Novartis Business Overview
  100. 8.17.3 Novartis Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Novartis Tumor Treatment Drug Product Portfolio
  102. 8.17.5 Novartis Recent Developments
  103. 8.18 Johnson & Johnson
  104. 8.18.1 Johnson & Johnson Company Information
  105. 8.18.2 Johnson & Johnson Business Overview
  106. 8.18.3 Johnson & Johnson Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Johnson & Johnson Tumor Treatment Drug Product Portfolio
  108. 8.18.5 Johnson & Johnson Recent Developments
  109. 8.19 Sanofi
  110. 8.19.1 Sanofi Company Information
  111. 8.19.2 Sanofi Business Overview
  112. 8.19.3 Sanofi Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Sanofi Tumor Treatment Drug Product Portfolio
  114. 8.19.5 Sanofi Recent Developments
  115. 8.20 Teva
  116. 8.20.1 Teva Company Information
  117. 8.20.2 Teva Business Overview
  118. 8.20.3 Teva Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Teva Tumor Treatment Drug Product Portfolio
  120. 8.20.5 Teva Recent Developments
  121. 8.21 Eisai
  122. 8.21.1 Eisai Company Information
  123. 8.21.2 Eisai Business Overview
  124. 8.21.3 Eisai Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Eisai Tumor Treatment Drug Product Portfolio
  126. 8.21.5 Eisai Recent Developments
  127. 8.22 Takeda
  128. 8.22.1 Takeda Company Information
  129. 8.22.2 Takeda Business Overview
  130. 8.22.3 Takeda Tumor Treatment Drug Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Takeda Tumor Treatment Drug Product Portfolio
  132. 8.22.5 Takeda Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst